| basic FUNCTION
| involved in regulation of T cell receptor-mediated cell death |
|
may be involved in interactions between activated |
|
T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death |
|
TNFRSF18, but also TNFSF18 is capable of transducing signals, and the consequences of TNFRSF18-TNFSF18 interaction may vary among different effector cell types, differ upon signal transduction via the receptor, the ligand, or both, depend on the level of an ongoing immune response  |
|
stimulation of TNFRSF18 on effector CD8 T cells results in high-avidity T cell responses to tumor-specific Ags, thereby inducing potent antitumor immunity in the absence of autoimmunity |
|
dexamethasone-inducible molecule in T cells |
|
ligation of TNFRSF18 had profound effects on kinase phosphorylation, surface receptor expression, suppressive activity, and cytokine production |
|
TNFRSF18 is a coactivating receptor that is constitutively expressed on Treg cells and induced on activated T cells |
|
contributes to TNFRSF9 expression on CD8 T cells upon their entry into the bone marrow (BM) or liver |
|
TNFRSF4, TNFRSF18 play important roles in regulating activities of effector and regulatory T cells (Treg) |
|
expressed on macrophages, drives cytokine release and T cell activation, resulting in neuropathic pain via TNFRSF18-dependent actions |
|
is likely a crucial player in the differentiation of thymic Tregs (tTregs), and expansion of both tTregs and peripheral Tregs (pTregs) |
|
TNFRSF18 co-stimulation mediates antitumor immunity by promoting TH9 cell differentiation and enhancing CTL responses |
